These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 27797594

  • 1. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
    Bergamini A, Ferrero S, Leone Roberti Maggiore U, Scala C, Pella F, Vellone VG, Petrone M, Rabaiotti E, Cioffi R, Candiani M, Mangili G.
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
    [Abstract] [Full Text] [Related]

  • 2. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D, Cristea M.
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [Abstract] [Full Text] [Related]

  • 3. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R.
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [Abstract] [Full Text] [Related]

  • 4. Exploiting the folate receptor α in oncology.
    Scaranti M, Cojocaru E, Banerjee S, Banerji U.
    Nat Rev Clin Oncol; 2020 Jun; 17(6):349-359. PubMed ID: 32152484
    [Abstract] [Full Text] [Related]

  • 5. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ.
    Cancer; 2017 Aug 15; 123(16):3080-3087. PubMed ID: 28440955
    [Abstract] [Full Text] [Related]

  • 6. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.
    Gynecol Oncol; 2017 Nov 15; 147(2):402-407. PubMed ID: 28843653
    [Abstract] [Full Text] [Related]

  • 7. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
    Azaïs H, Queniat G, Bonner C, Kerdraon O, Tardivel M, Jetpisbayeva G, Frochot C, Betrouni N, Collinet P, Mordon S.
    Int J Gynecol Cancer; 2015 Sep 15; 25(7):1194-200. PubMed ID: 26244757
    [Abstract] [Full Text] [Related]

  • 8. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
    Azaïs H, Schmitt C, Tardivel M, Kerdraon O, Stallivieri A, Frochot C, Betrouni N, Collinet P, Mordon S.
    Photodiagnosis Photodyn Ther; 2016 Mar 15; 13():130-138. PubMed ID: 26200606
    [Abstract] [Full Text] [Related]

  • 9. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
    Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD.
    Gynecol Oncol; 2013 Nov 15; 131(2):493-8. PubMed ID: 23863359
    [Abstract] [Full Text] [Related]

  • 10. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.
    Mol Cancer Ther; 2015 Jul 15; 14(7):1605-13. PubMed ID: 25904506
    [Abstract] [Full Text] [Related]

  • 11. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.
    Gynecol Oncol; 2018 Oct 15; 151(1):46-52. PubMed ID: 30093227
    [Abstract] [Full Text] [Related]

  • 12. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.
    J Clin Oncol; 2017 Apr 01; 35(10):1112-1118. PubMed ID: 28029313
    [Abstract] [Full Text] [Related]

  • 13. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ.
    Future Oncol; 2018 Jan 01; 14(2):123-136. PubMed ID: 29098867
    [Abstract] [Full Text] [Related]

  • 14. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ.
    Future Oncol; 2018 Jul 01; 14(17):1669-1678. PubMed ID: 29424243
    [Abstract] [Full Text] [Related]

  • 15. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.
    Hou Z, Gattoc L, O'Connor C, Yang S, Wallace-Povirk A, George C, Orr S, Polin L, White K, Kushner J, Morris RT, Gangjee A, Matherly LH.
    Mol Cancer Ther; 2017 May 01; 16(5):819-830. PubMed ID: 28138029
    [Abstract] [Full Text] [Related]

  • 16. Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.
    Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y.
    Mol Pharm; 2019 Sep 03; 16(9):3996-4006. PubMed ID: 31369274
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
    Farrell C, Schweizer C, Wustner J, Weil S, Namiki M, Nakano T, Nakai K, Phillips MD.
    Cancer Chemother Pharmacol; 2012 Nov 03; 70(5):727-34. PubMed ID: 22955257
    [Abstract] [Full Text] [Related]

  • 18. Role of farletuzumab in epithelial ovarian carcinoma.
    Jelovac D, Armstrong DK.
    Curr Pharm Des; 2012 Nov 03; 18(25):3812-5. PubMed ID: 22591419
    [Abstract] [Full Text] [Related]

  • 19. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L, Wang Y, Yao Y, Li W, Lai Q, Li J, Zhou Y, Kang T, Xie Y, Wu Y, Chen X, Yi C, Gou L, Yang J.
    Int J Gynecol Cancer; 2014 Sep 03; 24(7):1158-64. PubMed ID: 24987913
    [Abstract] [Full Text] [Related]

  • 20. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
    Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U.
    Int J Gynecol Cancer; 2024 Aug 05; 34(8):1119-1125. PubMed ID: 38858103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.